Small, dense low-density lipoprotein subclass pattern B: Issues for the clinician

Current Atherosclerosis Reports

Volumn 1, Issue 1, 1999, Pages 50-57

  Superko, H Robert ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Atherogenic Lipoprotein Profile; Coronary Artery Disease Patient; Coronary Artery Disease Risk Factor; Increase Coronary Artery Disease Risk; Subclass Pattern

Indexed keywords

LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ARTERIOSCLEROSIS; BLOOD; CLASSIFICATION; HUMAN; METABOLISM; PARTICLE SIZE; REVIEW; RISK FACTOR;

ARTERIOSCLEROSIS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; PARTICLE SIZE; RISK FACTORS;

EID: 0033157007     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-999-0050-6     Document Type: Article

References (57)

1. Superko HR: Inherited disorders in the lipoprotein system. A common cause of premature heart disease. In Women and Heart Disease. Edited by Julian DG and Wenger NK. London: Martin Dunitz; 1997: 49–67.
2. Goldbourt U, de Faire U, Berg K: Genetic factors in Coronary Heart Disease. Hingham: Kluwer Academic Publishers; 1994.
3. Higgins MW, Luepker RV: Trends and determinants of coronary heart disease mortality: International comparisons. Int J Epidemiol 1989:S1–S232.
4. Superko HR, Krauss RM: Coronary artery disease regression. convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994, 90:1056–1069.
5. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998, 279:1615–1622. DOI: 10.1001/jama.279.20.1615
6. Superko HR: What can we learn about dense LDL and lipoprotein particles from clinical trials? Curr Opin Lipidol 1996, 7:363–368.
7. Superko HR: New aspects of cardiovascular risk factors including small, dense LDL, homocysteinemia, and Lp(a). Curr Opin Cardiol 1995, 10:347–354. DOI: 10.1097/00001573-199507000-00002
8. Genest JJ, Martin-Munley SS, McNamara JR, et al.: Familial lipoprotein disorders in patients with premature CAD. Circulation 1992, 85:20205–2033.
9. Friedlander Y: Familial clustering of cornary heart disease: a review of its significance and role as a risk factor for the disease. In Genetic factors in Coronary Heart Disease. Edited by Goldbourt U, de Faire U, Berg K. Hingham: Kluwer Academic Publishers; 1994:37–53.
10. Hamsten A, de Faire U: Risk factors for coronary artery disease in families of young men with myocardial infarction. Am J Cardiol 1987, 59:14–19. DOI: 10.1016/S0002-9149(87)80061-9
11. Superko HR: Beyond LDL-C reduction. Circulation 1996, 94:2351–2354.
12. Deckelaum RJ, Olivecrona T, Eisenberg S: Plasma lipoproteins in hyperlipidemia: roles of neutral lipid exchange and lipase. In Treatment of Hyperlipoproteinemia. Edited by Carlson LA, Olsson AG. (New York): Raven Press; 1984:85–93.
13. Grundy SM: Hyperlipoproteinemia: metabolic basis and rationale for therapy. Am J Cardiol 1984, 54:20C-26C. DOI: 10.1016/0002-9149(84)90852-X
14. Miller NE: Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987, 113:589–597. DOI: 10.1016/0002-8703(87)90638-7
15. Superko HR, Bachorik PS, Wood PD: High-density lipoprotein cholesterol measurements. JAMA 1986, 256:2714–2717. DOI: 10.1001/jama.256.19.2714
16. Krauss RM, Blanche PJ: Detection and quantitation of LDL subfractions. Curr Opin Lipidol 1992, 3:377–383. DOI: 10.1097/00041433-199212000-00005
17. Gofman JW, Young W, Tandy R: Ischemic heart disease, atherosclerosis and longevity. Circulation 1996, 34:679–697.
18. Superko HR: Did Grandma give you heart disease? The new battle against coronary artery disease. Am J Card 1998, 82:34–46. DOI: 10.1016/S0002-9149(98)00771-1
19. Krauss RM: Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994, 5:339–349. DOI: 10.1097/00041433-199410000-00005
20. Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prespective results from the Quebec cardiovascular study. Circulation 1997, 95:69–75.
21. Superko HR: What can we learn about dense LDL and lipoprotein particles from clinical trials? Curr Opin Lipidol 1996, 7:363–368. DOI: 10.1097/00041433-199612000-00004
22. Austin MA, Breslow JL, Hennekens CH, et al.: Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917–1921. DOI: 10.1001/jama.260.13.1917
23. Gardner CD, Fortmann SP, Krauss RM: Small low density lipoprotein particles are associated with the incidence of coronary artery disease in men and women. JAMA 1996, 276:875–881. DOI: 10.1001/jama.276.11.875
24. Stampfer MJ, Krauss RM, Blanche PJ, et al.: A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction. JAMA, 1996, 276:882–888. DOI: 10.1001/jama.276.11.882
25. Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prespective results from the Quebec cardiovascular study. Circulation 1997, 95:69–75.
26. Austin MA, Kamigaki A, Hokanson JE: Low-density lipoprotein particle size is a risk factor for coronary heart disease independent of triglyceride and HDL cholesterol: a meta-analysis of three prospective studies in men. Circulation 1999, 99:1124.
27. Miller BD, Alderman EL, Haskell WL, et al.: Predominance of dense low-density lipoprotein particles predicts angiographic benefit or therapy in the Stanford Coronary Risk Intervention project. Circulation 1996, 94:2146–2153.
28. Superko HR, Krauss RM, Alderman EM: Diabetics have rapid arteriographic coronary disease progression but also arteriographic benefit from risk reduction. Circulation 1997, 96:4289.
29. Watts GF, Mandalia S, Brunt JN, et al.: Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St Thomas’ Atherosclerosis Regression Study (STARS). Metabolism 1993, 42:1461–1467. DOI: 10.1016/0026-0495(93)90199-X
30. Zambonj A, Hokanson JE, Brown BG, Brunzell JD: Evidence for a new pathophysiological mechanism for coronary artery disease regression. Hepatic lipase-mediated changes in LDL density. Circulation 1999, 99:1959–1964.
31. Superko HR: The atherogenic lipoprotein profile. Science and Medicine 1997, 4:36–45.
32. Nishina PM, Johnson JP, Naggert JK, et al.: Linkage of atherogenic lipoprotein phenotype to the low-density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci USA 1992, 89:708–712. DOI: 10.1073/pnas.89.2.708
33. Rotter JI, Bu X, Cantor R, et al.: Multilocus genetic determination of LDL particle size in coronary artery disease families Clin Res 1994, 42:16A.
34. Superko HR, Krauss RM, Miller B: Prediction of LDL subclass pattern from Trig, HDLC, LDLC.apoB. Cardiovascular Health Feb 19, 1998.
35. Lindgren FT, Jensen LC, Hatach FT: The isolation and quantitative analysis of serum lipoproteins. In Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism. Nelson GJ. New York: Wiley-Interscience; 1972:181–274.
36. Krauss RM, Blanche PJ: Detection and quantitation of LDL subfractions. Curr Opin Lipidol 1992, 3:377–383. DOI: 10.1097/00041433-199212000-00005
37. Superko HR, Krauss RM, Haskell WL, Stanford Coronary Risk Intervention Project Investigators: Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Atherosclerosis 1993, 101:1–8. DOI: 10.1016/0021-9150(93)90095-C
38. Superko HR, Wood PD, Krauss RM: Effect of alpha- and selective beta-blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclasses, and postprandial lipemia. Am J Med 1989, 86:26–31. DOI: 10.1016/0002-9343(89)90125-3
39. Williams PT, Krauss RM, Vranizan KM, Wood PD: Changes in lipoprotein subfractions during diet-induced and exercise-induced weight loss in moderately overweight men. Circulation 1990, 81:1293–1304.
40. Superko HR, Krauss RM: Reduction of small, dense LDL by gemfibrozil in LDL subclass pattern B. Circulation 1995, 92:1–250.
41. Wood PD, Stefanick ML, Dreon DM, et al.: Changes in plasma lipids and pipoproteins during weight loss by dieting versus exercise in overweight men. N Eng J Med 1988, 319:1173–1179. DOI: 10.1056/NEJM198811033191801
42. Dreon DM, Krauss RM: Gene-diet interactions in lipoprotein metabolism. Mongr Hum Genet 1992, 14:325–349.
43. Dreon DM, Fernstrom H, Miller B, Krauss RM: Low density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB J 1994, 8:121–126.
44. Superko HR, KOS investigators: Effect of nicotinic acid on LDL subcalss patterns. Circulation 1994, 90:1–504.
45. Homma Y, Ozawa H, Kobayashi T, et al.: Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis 1995:114:223–234. DOI: 10.1016/0021-9150(94)05487-4
46. Cheung MC, Austin MA, Moulin P, et al.: Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 1993, 102:107–119. DOI: 10.1016/0021-9150(93)90089-D
47. Superko HR, Krauss RM, DiRicco C: Effect of HMGCoA reductase inhibitor (Fluvastatin) on LDL peak particle diameter. Am J Cardiol 1997, 80:78–81. DOI: 10.1016/S0002-9149(97)00288-9
48. O’Keefe JH Jr, Harris WS, Nelson J, Windsor SL: Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol 1995, 76:480–484. DOI: 10.1016/S0002-9149(99)80134-9
49. Castelli WP, Doyle JT, Gordon T, et al.: HDL cholesterol and other lipids in coronary heart disease. Circulation 1977, 55:767–772.
50. Berge KG, Canner PL, Hainline A: High density lipoprotein cholesterol and prognosis after myocardial infatrction. Circulation 1982, 66:1176–1181.
51. Goldbourt U, Cohen L, Neufeld HN: High density lipoprotein cholesterol: prognosis after myocardial infarction. Int J Epidemiol 1986, 15:51–55. DOI: 10.1093/ije/15.1.51
52. Vergani C, Beattale G. Familial hypo-alpha-lipoproteinemia. Clin Chim Acta 1981, 114:45–52. DOI: 10.1016/0009-8981(81)90226-6
53. Marcil M, Boucher B, Krimbou L, et al.: Severe familial HDL deficiency in French-Canadian kindreds. Arterioscler Thromb Vasc Biol 1995, 15:1015–1024.
54. Ordovas JM, Schaefer EJ, Salem D, et al.: Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. N Eng J Med 1986, 314:671–677. DOI: 10.1056/NEJM198603133141102
55. King JM, Crouse JR, Terry JG, et al.: Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med 1994, 97:323–331. DOI: 10.1016/0002-9343(94)90298-4
56. Miller M, Bachorik PS, McCrindle BW, Kwiterovich PO: Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study. Am J Med 1993, 94:7–20. DOI: 10.1016/0002-9343(93)90113-4
57. Superko HR, Krauss RM: Differential effect on HDL of niacin and resin in LDL subclass pattern A and B subjects. Circulation 1993, 88:I-386.